Chinese coronavirus-vaccine maker Sinovac Biotech is good at getting its products to market. It was first to begin clinical trials of a SARS vaccine in 2003 and first to bring a swine flu vaccine to consumers in 2009.
Its CEO was also bribing China’s drug regulator for vaccine approvals during that time, court records show.
Sinovac has acknowledged the bribery case involving its CEO, saying in regulatory filings that he cooperated with prosecutors and was not charged. The CEO said in testimony he could not refuse demands for money from a regulatory official.
Sinovac has not been involved in safety scandals, and there is no evidence that any of the vaccines approved in cases involving bribery were faulty. But some medical experts say that extra scrutiny of Sinovac’s drug claims is justified, given its record of moral flexibility.
The article has been summarised and the original full article can be found at washingtonpost.com.
(Photo: Wang Zhao/AFP/Getty Images)